STSA — Satsuma Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
- $36.47m
- -$4.90m
Annual income statement for Satsuma Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 7.51 | 28.9 | 48.3 | 51.2 | 70.9 |
| Operating Profit | -7.51 | -28.9 | -48.3 | -51.2 | -70.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -7.35 | -28.2 | -47.6 | -51.2 | -70.1 |
| Net Income After Taxes | -7.35 | -28.2 | -47.6 | -51.2 | -70.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -7.35 | -28.2 | -47.6 | -51.2 | -70.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -7.35 | -28.2 | -47.6 | -51.2 | -70.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.457 | -1.62 | -2.73 | -1.75 | -1.82 |
| Dividends per Share |